TP-238

Cat. No.:	HY-114205
CAS No.:	2415263-04-4
Molecular Formula:	$C_{22}H_{30}N_6O_3S$
Molecular Weight:	458.58
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TP-238 is a potent and selective dual CECR2/BPTF probe with IC_{50} values of 30 nM and 350 nM, respectively. TP-238 also inhibits BRD9 with a pIC_{50} of 5.9 and is less active against other 338 kinases[1][2].			
IC_{50} & Target	CECR2 30 nM (IC_{50})	CECR2 10 nM (Kd)	CECR2 7.5 (pIC_{50})	BPTF 350 nM (IC_{50})
	BPTF 120 nM (Kd)	BPTF 6.5 (pIC_{50})	BRD9 5.9 (pIC_{50})	
In Vitro	TP-238 has on target biochemical activity of 10-30 nM with CECR2 and 100-350 nM with BPTF. TP-238 displays potency for both CECR2 (pIC50 of 7.5) and BPTF (pIC50 of 6.5) in an Alpha screen assay. Isothermal titration calorimetry (ITC) shows TP-238 with a Kd of 10 nM for CECR2 and 120 nM for BPTF[1][2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Michael A Clegg, et al. Advancements in the Development of non-BET Bromodomain Chemical Probes. ChemMedChem. 2019 Feb 19;14(4):362-385.

[2]. Peter D Ycas, et al. New Inhibitors for the BPTF Bromodomain Enabled by Structural Biology and Biophysical Assay Development. Org Biomol Chem. 2020 Jun 26.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA